Germline truncating mutations in CDKN2A, such as E119X and Q50X, have recently been identified in patients with familial “pancreatic cancer plus melanoma syndrome”, a rare cancer predisposition syndrome associated with increased risk of pancreatic cancer and malignant melanoma [14]. This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.